Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRO-CKD
NCT02502981Phase 4Unknown
- Sponsor
- University Hospitals Birmingham
- Start
- Jun 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of spironolactone in chronic kidney disease (CKD) (2 arms), sponsored by University Hospitals Birmingham. Primary endpoint: Change in Left Ventricular Mass at 40 weeks. Status: unknown.
02
Drugs
spironolactone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02502981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502981.